Showing results (11-20 of 111) with videos related to
Sort By:
Pageof 12
Pharmacoepidemiology and Drug Safety|July 3, 2023
Decision and timing of safety-related labeling changes for new drugs in Japan: Comparison with the United States and the European UnionKoichi Fukuda, Mamoru NarukawaJournal of Clinical Pharmacology|February 18, 2026
Concentration-QTc Analysis as an Alternative to TQT Studies: Findings From QT Evaluation and Safety Labeling Decisions in JapanTsubasa Wakabayashi, Mamoru NarukawaClinical Pharmacology and Therapeutics|May 5, 2026
Comparative Analysis of Additional Risk Minimization Measures in the Risk Management Plan in the European Union and JapanTeruyuki Honda, Mamoru NarukawaDiabetes Research and Clinical Practice|June 21, 2016
Meta-analysis of dipeptidyl peptidase-4 inhibitors use and cardiovascular risk in patients with type 2 diabetes mellitusMasayuki Kaneko, Mamoru NarukawaInternational Journal of Clinical Pharmacology and Therapeutics|August 3, 2017
Predictive factors for the effect of acid-reducing agents on drug exposureMasahiko Sato, Mamoru NarukawaTherapeutic Drug Monitoring|March 30, 2005
A note on population pharmacokinetic studies with a single sampling designMamoru Narukawa, Akifumi YafuneTherapeutic Innovation & Regulatory Science|May 2, 2018
Comparison of Serious Adverse Event Profiles Among Antirheumatic Agents Using Japanese Adverse Drug Event Report DatabaseYomei Matsuoka, Mamoru NarukawaPharmacoepidemiology and Drug Safety|September 7, 2007
A note on post-marketing safety study design to characterise time-dependent adverse eventsMamoru Narukawa, Akifumi YafunePharmaceutical Medicine|November 2, 2021
Key Characteristics of Database Studies on Drug Effectiveness in the Postmarketing Stage: A Systematic ReviewChihaya Shiragasawa, Mamoru NarukawaTherapeutic Innovation & Regulatory Science|April 28, 2022
Randomized Controlled Trial Data for New Drug Application for Rare Diseases in JapanYosuke Kubota, Mamoru NarukawaPageof 12